drugset / Trial / NCT00289016
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
Timeline
- Start
- 2005-12
- Primary completion
- 2008-12
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talimogene Laherparepvec | Other / unclassified | 4 ml | Other |